Mereo BioPharma Group PLC ADR (MREO) — Cash Flow-to-Debt Ratio
Mereo BioPharma Group PLC ADR (MREO) has a Cash Flow-to-Debt Ratio of -0.66x as of March 2026, meaning its operating cash flow of $-4.31 Million could theoretically repay -1% of its total liabilities ($6.56 Million) in one year. Check Mereo BioPharma Group PLC ADR investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Mereo BioPharma Group PLC ADR Cash Flow-to-Debt Ratio (2015–2025)
Historical debt coverage capacity for Mereo BioPharma Group PLC ADR across 11 annual periods. Also explore Mereo BioPharma Group PLC ADR balance sheet assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Mereo BioPharma Group PLC ADR (2015–2025)
Year-by-year debt coverage analysis for Mereo BioPharma Group PLC ADR. For market capitalisation and broader financial context, see MREO market cap overview.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -6.19x | $-30.97 Million | $5.00 Million | ▼ -190.9% |
| 2024 | -2.13x | $-32.83 Million | $15.42 Million | ▼ -60.8% |
| 2023 | -1.32x | $-21.13 Million | $15.96 Million | ▲ +29.5% |
| 2022 | -1.88x | $-48.82 Million | $26.01 Million | ▼ -1279.0% |
| 2021 | -0.14x | $-7.07 Million | $51.95 Million | ▲ +62.5% |
| 2020 | -0.36x | $-38.62 Million | $106.55 Million | ▲ +63.2% |
| 2019 | -0.98x | $-60.22 Million | $61.19 Million | ▼ -46.8% |
| 2018 | -0.67x | $-23.14 Million | $34.51 Million | ▲ +29.4% |
| 2017 | -0.95x | $-32.15 Million | $33.85 Million | ▲ +74.0% |
| 2016 | -3.65x | $-27.40 Million | $7.51 Million | ▼ -213.6% |
| 2015 | -1.16x | $-6.70 Million | $5.76 Million | — |